Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo

Journal of Hepatology

Volumn 60, Issue 5, 2014, Pages 985-994

  Berger, Michael ^a,b   Neth, Olaf ^a   Ilmer, Matthias ^c   Garnier, Agnès ^b   Salinas Martín, Manuel Vicente ^d   De Agustín Asencio, Juan Carlos ^a   Von Schweinitz, Dietrich ^b   Kappler, Roland ^b   Muñoz, Miguel ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d HOSPITAL UNIVERSITARIO JUAN RAMÓN JIMÉNEZ   (Spain)

Author keywords

Anti tumor target; Apoptosis; Aprepitant; Hepatoblastoma (HB); Neurokinin 1 receptor (NK1R); Substance P (SP); Xenograft

Indexed keywords

APREPITANT; CYTOSTATIC AGENT; ISOPROTEIN; MORPHOLINE DERIVATIVE; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; SUBSTANCE P;

ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; CELL PROLIFERATION; CHILD; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; FEMALE; GENE EXPRESSION; GENETICS; HEPATOBLASTOMA; HEPG2 CELL LINE; HUMAN; LIVER NEOPLASMS; METABOLISM; MOUSE; NEOVASCULARIZATION, PATHOLOGIC; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CHILD; CYTOSTATIC AGENTS; DRUG SYNERGISM; FEMALE; GENE EXPRESSION; HEP G2 CELLS; HEPATOBLASTOMA; HUMANS; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; MORPHOLINES; NEOVASCULARIZATION, PATHOLOGIC; NEUROKININ-1 RECEPTOR ANTAGONISTS; PROTEIN ISOFORMS; RECEPTORS, NEUROKININ-1; SUBSTANCE P; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84898828399     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2013.12.024     Document Type: Article

References (34)

1. D. von Schweinitz Hepatoblastoma: recent developments in research and treatment Semin Pediatr Surg 21 2012 21 30
2. D. von Schweinitz Management of liver tumors in childhood YSPSU 15 2006 17 24
3. R. Kappler, and D. Schweinitz von A better way forward: targeting hedgehog signaling in liver cancer Front Biosci (Schol Ed) 4 2012 277 286
4. S. Warmann, M. Hunger, B. Teichmann, P. Flemming, K.F. Gratz, and J. Fuchs The role of the MDR1 gene in the development of multidrug resistance in human hepatoblastoma: clinical course and in vivo model Cancer 95 2002 1795 1801
5. S.W. Warmann, H. Frank, H. Heitmann, P. Ruck, T. Herberts, and G. Seitz et al. Bcl-2 gene silencing in pediatric epithelial liver tumors J Surg Res 144 2008 43 48
6. S.W. Warmann, S. Armeanu, H. Frank, H. Buck, F. Graepler, and M.-L. Lemken et al. In vitro gene targeting in human hepatoblastoma Pediatr Surg Int 22 2006 16 23
7. M. Muñoz, M. Rosso, and R. Coveñas A new frontier in the treatment of cancer: NK-1 receptor antagonists Curr Med Chem 17 2010 504 516
8. M. Muñoz, M. Rosso, and R. Coveñas The NK-1 receptor: a new target in cancer therapy Curr Drug Targets 12 2011 909 921
9. M. Muñoz, and R. Coveñas Neurokinin-1 receptor: a new promising target in the treatment of cancer Discov Med 10 2010 305 313
10. M. Rosso, M. Muñoz, and M. Berger The role of neurokinin-1 receptor in the microenvironment of inflammation and cancer Sci World J 2012 2012 1 21
11. M. Muñoz, and M. Rosso The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug Invest New Drugs 28 2010 187 193
12. M.S. Kramer Distinct mechanism for antidepressant activity by blockade of central substance P receptors Science 281 1998 1640 1645
13. F. Wagner, B. Henningsen, C. Lederer, M. Eichenmüller, J. Gödeke, and J. Müller-Höcker et al. Rapamycin blocks hepatoblastoma growth in vitro and in vivo implicating new treatment options in high-risk patients Eur J Cancer 2012 1 9
14. M.E.U. ller, B. Hemmerlein, D. Schweinitz von, and R. Kappler Betulinic acid induces apoptosis and inhibits hedgehog signalling in rhabdomyosarcoma Br J Cancer 103 2010 43 51
15. M. Eichenmüller, I. Gruner, B. Hagl, B. Häberle, J. Müller-Höcker, and D. Schweinitz von et al. Blocking the hedgehog pathway inhibits hepatoblastoma growth Hepatology 49 2009 482 490
16. M. Muñoz, A. Pérez, M. Rosso, C. Zamarriego, and R. Rosso Antitumoral action of the neurokinin-1 receptor antagonist L-733 060 on human melanoma cell lines Melanoma Res 14 2004 183 188 [Internet]
17. M. Berger, C.-Y. Hsieh, M. Bakele, V. Marcos, N. Rieber, and M. Kormann et al. Neutrophils express distinct RNA receptors in a non-canonical way J Biol Chem 287 2012 19409 19417
18. M. Muñoz, M. Rosso, A. Pérez, R. Coveñas, R. Rosso, and C. Zamarriego et al. The NK1 receptor is involved in the antitumoural action of L-733,060 and in the mitogenic action of substance P on neuroblastoma and glioma cell lines Neuropeptides 39 2005 427 432 [Internet]
19. E. Gillespie, S.E. Leeman, L.A. Watts, J.A. Coukos, M.J. O'Brien, and S.R. Cerda et al. Truncated neurokinin-1 receptor is increased in colonic epithelial cells from patients with colitis-associated cancer Proc Natl Acad Sci U S A 108 2011 17420 17425
20. L.L. Dupuis, K. Lingertat-Walsh, and S.E. Walker Stability of an extemporaneous oral liquid aprepitant formulation Support Care Cancer 17 2008 701 706
21. J.M.Y. Ng, and T. Curran The Hedgehog's tale: developing strategies for targeting cancer Nat Rev Cancer 11 2011 493 501
22. B. Chen, M.E. Dodge, W. Tang, J. Lu, Z. Ma, and C.-W. Fan et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer Nat Chem Biol 5 2009 100 107
23. F.D. Tattersall, W. Rycroft, M. Cumberbatch, G. Mason, S. Tye, and D.J. Williamson et al. The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets Neuropharmacology 39 2000 652 663
24. M. Muñoz, M. Berger, M. Rosso, A. Gonzalez-Ortega, A. Carranza, and R. Coveñas Anti-tumor activity of neurokinin-1 receptor antagonists on human osteosarcoma MG-63 xenograft Int J Oncol 44 2014 137 146
25. C. Mayordomo, S. García-Recio, E. Ametller, P. Fernández-Nogueira, E.M. Pastor-Arroyo, and L. Vinyals et al. Targeting of substance P induces cancer cell death and decreases the steady state of EGFR and Her2 J Cell Physiol 227 2012 1358 1366
26. W.Z. Ho, J.P. Lai, X.H. Zhu, M. Uvaydova, and S.D. Douglas Human monocytes and macrophages express substance P and neurokinin-1 receptor J Immunol 159 1997 5654 5660
27. L. Boulter, O. Govaere, T.G. Bird, S. Radulescu, P. Ramachandran, and A. Pellicoro et al. Macrophage-derived Wnt opposes Notch signaling to specify hepatic progenitor cell fate in chronic liver disease Nat Med 18 2012 572 579
28. H.J. Patel, S.H. Ramkissoon, P.S. Patel, and P. Rameshwar Transformation of breast cells by truncated neurokinin-1 receptor is secondary to activation by preprotachykinin-A peptides Proc Natl Acad Sci U S A 102 2005 17436 17441
29. S.H. Ramkissoon, P.S. Patel, M. Taborga, and P. Rameshwar Nuclear factor-kappaB is central to the expression of truncated neurokinin-1 receptor in breast cancer: implication for breast cancer cell quiescence within bone marrow stroma Cancer Res 67 2007 1653 1659
30. C. Palma, M. Bigioni, C. Irrissuto, F. Nardelli, C.A. Maggi, and S. Manzini Anti-tumour activity of tachykinin NK1 receptor antagonists on human glioma U373 MG xenograft Br J Cancer 82 2000 480 487
31. M. Bigioni, A. Benzo, C. Irrissuto, C.A. Maggi, and C. Goso Role of NK-1 and NK-2 tachykinin receptor antagonism on the growth of human breast carcinoma cell line MDA-MB-231 Anticancer Drugs 16 2005 1083 1089
32. S. Garcia-Recio, G. Fuster, P. Fernandez-Nogueira, E.M. Pastor-Arroyo, S.Y. Park, and C. Mayordomo et al. Substance P autocrine signaling contributes to persistent HER2 activation that drives malignant progression and drug resistance in breast cancer Cancer Res 73 2013 6424 6434
33. S. Guha, G. Eibl, K. Kisfalvi, R.S. Fan, M. Burdick, and H. Reber et al. Broad-spectrum G protein-coupled receptor antagonist, [D-Arg1, D-Trp5,7,9, Leu11]SP: a dual inhibitor of growth and angiogenesis in pancreatic cancer Cancer Res 65 2005 2738 2745
34. I. Herpfer, and K. Lieb Substance P, receptor antagonists in psychiatry: rationale for development and therapeutic potential CNS Drugs 19 2005 275 293